Role of PARP Inhibitors in Cancer Biology and Therapy

Autor Davar, D., Beumer, J.H., Hamieh, L., Tawbi, H.
Vydáno 2012

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry

Autor Beumer, J. H., Garner, R. C., Cohen, M. B., Galbraith, S., Duncan, G. F., Griffin, T., Beijnen, J. H., Schellens, J. H. M.
Vydáno 2007

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

Autor Nabhan, C, Villines, D, Valdez, T V, Tolzien, K, Lestingi, T M, Bitran, J D, Christner, S M, Egorin, M J, Beumer, J H
Vydáno 2012

Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis

Autor Tawbi, H. A., Beumer, J. H., Tarhini, A. A., Moschos, S., Buch, S. C., Egorin, M. J., Lin, Y., Christner, S., Kirkwood, J. M.
Vydáno 2013

A Phase I Trial of Isolated Hepatic Perfusion (IHP) Using 5-FU and Oxaliplatin in Patients with Unresectable Isolated Liver Metastases from Colorectal Cancer

Autor Magge, D., Zureikat, A. H., Bartlett, D. L., Holtzman, M. P., Choudry, H. A., Beumer, J. H., Pingpank, J. F., Holleran, J. L., Strychor, S., Cunningham, D. E., Jones, H. L., Zeh, H. J.
Vydáno 2013

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

Autor Kelley, R K, Hwang, J, Magbanua, M J M, Watt, L, Beumer, J H, Christner, S M, Baruchel, S, Wu, B, Fong, L, Yeh, B M, Moore, A P, Ko, A H, Korn, W M, Rajpal, S, Park, J W, Tempero, M A, Venook, A P, Bergsland, E K
Vydáno 2013